Cargando…
Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer
Breast cancer is the most common cancer in women, with 1.7 million new cases each year. As early diagnosis and prognosis are crucial factors in cancer treatment, we investigated potential DNA methylation biomarkers of the tumour suppressor family Ras-association domain family (RASSF). Promoter hyper...
Autores principales: | Richter, Antje M., Walesch, Sara K., Dammann, Reinhard H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810110/ https://www.ncbi.nlm.nih.gov/pubmed/26927176 http://dx.doi.org/10.3390/cancers8030026 |
Ejemplares similares
-
Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma
por: Richter, Antje M., et al.
Publicado: (2013) -
The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancer
por: Richter, A M, et al.
Publicado: (2012) -
RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice
por: Richter, Antje M., et al.
Publicado: (2020) -
RASSF10 Is a TGFβ-Target That Regulates ASPP2 and E-Cadherin Expression and Acts as Tumor Suppressor That Is Epigenetically Downregulated in Advanced Cancer
por: Richter, Antje M., et al.
Publicado: (2019) -
The SARAH Domain of RASSF1A and Its Tumor Suppressor Function
por: Dittfeld, Claudia, et al.
Publicado: (2012)